Search Results for "frovatriptan"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for frovatriptan. Results 1 to 3 of 3 total matches.
See also: Frova

Comparison Table: Triptans for Migraine (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023  (Issue 1678)
Almotriptan Eletriptan Frovatriptan Naratriptan Rizatriptan Sumatriptan1 Zolmitriptan Brand Name ...
View the Comparison Table: Triptans for Migraine
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e97-9   doi:10.58347/tml.2023.1678b |  Show IntroductionHide Introduction

Atogepant (Qulipta) for Migraine Prevention

   
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021  (Issue 1636)
frovatriptan [Frova, and generics] or naratriptan [Amerge, and generics]) for several days before and after ...
Atogepant (Qulipta – Abbvie), an oral small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist ("gepant"), has been approved by the FDA for prevention of episodic migraine in adults. It is the second oral CGRP receptor antagonist to be approved in the US for this indication; the first was rimegepant (Nurtec ODT), which is also approved for acute treatment of migraine. Parenteral CGRP monoclonal antibodies are approved for prevention of migraine (see Table 3).
Med Lett Drugs Ther. 2021 Nov 1;63(1636):169-71 |  Show IntroductionHide Introduction

Drugs for Migraine

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023  (Issue 1678)
doses). The longer-acting oral triptans naratriptan and frovatriptan are generally better tolerated ...
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine in most patients without vascular disease. Treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96   doi:10.58347/tml.2023.1678a |  Show IntroductionHide Introduction